Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22270710 | 1.00 | IDO1 (0.45) | IDO1CYP2C9CYP2C8TDO2KCNH2 | |
| SCHEMBL21213988 | 0.86 | IDO1 (0.48) | IDO1CYP2C9CYP2C8TDO2KCNH2 | |
| SCHEMBL30495391 | 0.86 | IDO1 (0.48) | IDO1CYP2C9CYP2C8TDO2KCNH2 | |
| SCHEMBL22387407 | 0.86 | IDO1 (0.45) | IDO1CYP2C9CYP2C8TDO2KCNH2 | |
| SCHEMBL22270972 | 0.84 | IDO1 (0.47) | IDO1CYP2C9CYP2C8TDO2KCNH2 | |
| SCHEMBL22270748 | 0.83 | IDO1 (0.45) | IDO1CYP2C9CYP2C8TDO2KCNH2 | |
| SCHEMBL22270743 | 0.83 | IDO1 (0.45) | IDO1CYP2C9CYP2C8TDO2KCNH2 | |
| SCHEMBL22387556 | 0.83 | IDO1 (0.45) | IDO1CYP2C9CYP2C8TDO2KCNH2 | |
| SCHEMBL22387554 | 0.83 | IDO1 (0.45) | IDO1CYP2C9CYP2C8TDO2KCNH2 | |
| SCHEMBL28332972 | 0.83 | IDO1 (0.45) | IDO1CYP2C9CYP2C8TDO2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD (CN) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | IDO1, HDAC1, HDAC2 | IDO1 1/4885CYP2C9 3122/4885CYP2C8 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.